ArticleScientific reports2017
Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- A Biomimetic Self-Adjuvanting Glycoprotein Vaccine Platform Elicits Potent Antitumor Immunity against GD2-Positive Cancers.JACS Au · 2026Article
- Monophosphoryl Lipid A-2,4-Dinitrophenylamine Conjugates Are Potent Adjuvants for Carbohydrate and Protein Vaccines.JACS Au · 2025Article
- Glycoconjugate vaccines: platforms and adjuvants for directed immunity.Glycobiology · 2024Review
- Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants.Journal of medicinal chemistry · 2024Article
- NOD-scid IL2rγnull mice lacking TLR4 support human immune system development and the study of human-specific innate immunity.Journal of leukocyte biology · 2023Article
- Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.Chemical reviews · 2022Review
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.Frontiers in chemistry · 2022Article
- Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development.Chemical science · 2021Article
- Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action.Nature reviews. Chemistry · 2021Review
- Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.Advances in biochemical engineering/biotechnology · 2021Article
- Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.Carbohydrate research · 2020Article
- Synthetic carbohydrate-based vaccines: challenges and opportunities.Journal of biomedical science · 2020Review
- Past, Present, and Future of Anticancer Nanomedicine.International journal of nanomedicine · 2020Review
- Preparation and in vivo evaluation of glyco-gold nanoparticles carrying synthetic mycobacterial hexaarabinofuranoside.Beilstein journal of nanotechnology · 2020Article
- Synthesis of Lewis Y Analogues and Their Protein Conjugates for Structure-Immunogenicity Relationship Studies of Lewis Y Antigen.The Journal of organic chemistry · 2019Article
- Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants.International journal of molecular sciences · 2019Review
- Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.Molecules (Basel, Switzerland) · 2018Review
- Engineering a new generation of carbohydrate-based vaccines.Current opinion in chemical engineering · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
An efficient method was developed for the synthesis of a GM2 derivative suitable for the conjugation with various biomolecules. This GM2 derivative was covalently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic cancer vaccines. Immunological evaluations of the resultant conjugates in mice revealed that they elicited robust GM2-specific overall and IgG antibody responses. Moreover, the GM2-MPLA conjugate was disclosed to elicit strong immune responses without the use of an adjuvant, proving its self-adjuvant property. The antisera of both conjugates showed strong binding and mediated similarly effective complement-dependent cytotoxicity to GM2-expressing cancer cell line MCF-7. Based on these results, it was concluded that both GM2-MPLA and GM2-KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which has homogeneous and well-defined structure and self-adjuvant property, deserves more attention and studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.